At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 19 enrolled
Drug / intervention
68Ga-RM2 (RM2) +1 moreradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of 68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating 68Ga-RM2 (RM2) and PET/CT Scan for Prostate Cancer. Completed, enrolled 19 participants across 1 site.
Detailed Summary
The purpose of this study is to see if a new diagnostic research agent named 68Ga-RM2 can show prostate cancer on a PET/CT scan. 68Ga-RM2 stands for Galium-68 labeled DOTA-4-amino-1-carboxymethylpiperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2. This study is being done because there are unmet medical needs to improve the current ways of detecting prostate cancers before surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartSep 2015
First PostedSep 2015
Primary CompletionJun 2020
TodayJul 2026
First PostedSep 24, 2015
Enrollment StartSep 21, 2015
Primary CompletionJun 18, 2020
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 10.8 years ago
Interventions
68Ga-RM2 (RM2)radiation
PET/CT Scandevice